title: Interim Results on the Influence of Lanreotide on Uptake of [68Ga]-DOTATATE in Patients With Metastatic or Unresectable NET: No Evidence for Discontinuation of Lanreotide Before [68Ga]-DOTATATE PET/CT.
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D018278:Carcinoma, Neuroendocrine / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009942:Organometallic Compounds; D010456:Peptides, Cyclic / Q000494:pharmacology* / Q000627:therapeutic use; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods / Q000592:standards; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; C060347:lanreotide; D013004:Somatostatin; C513399:gallium Ga 68 dotatate